Kyowa Kirin Co Ltd (TSE: 4151), a Japan-based Global Specialty Pharmaceutical Company, announced on Tuesday that it has enrolled its first subject in a phase two clinical trial, multi-centre, randomised, double-masked, parallel group study of tivozanib eye drops (KHK4951).
The study is to assess the efficacy and safety of KHK4951 in patients with diabetic macular edema (DME). KHK4951 is a novel nano-crystalised tivozanib eye drop designed for delivery to the posterior ocular tissues and is being developed as a potential treatment option for neovascular (wet) age-related macular degeneration (nAMD) and DME.
Presently, an oral formulation of tivozanib is marketed as FOTIVDA in the US by AVEO Oncology, an LG Chem Company, and in Europe by EUSA Pharma (UK) Ltd for another indication.
The Phase two study will be enrolling 150 subjects with DME across the US, Japan, Australia and South Korea. The primary outcome measure is reduction of 15 or more letters from baseline in BCVA (Best Corrected Visual Acuity) as measured by the ETDRS visual acuity chart.
Transgene teams up with ProBioGen for individualised cancer vaccines
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Neogap Therapeutics partners with NorthX Biologics to enhance cancer cell therapy production
Medivir partners with Eisai to evaluate fostrox in liver cancer
Bexion Pharmaceuticals reports release of first-in-human data from Phase 1 study of BXQ-350
HUTCHMED receives milestone payment from Takeda for FRUZAQLA sales
Hemogenyx Pharmaceuticals schedules Phase i clinical trial for HEMO-CAR-T
SciBase and Kilabs partner to advance skin cancer diagnostics in Italy
Henlius and Organon announce FDA acceptance of BLA for denosumab biosimilar, HLX14
I-Mab announces presentation of Phase 1 dose data for givastomig at SITC 2024